The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
